Skip Navigation


JAC Advance Access originally published online on March 28, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/5/1095    most recent
dkg199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stebbing, J.
Right arrow Articles by Gazzard, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stebbing, J.
Right arrow Articles by Gazzard, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 1095-1098
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

How does HAART lead to the resolution of Kaposi’s sarcoma?

Justin Stebbing*, Simon Portsmouth and Brian Gazzard

Department of Immunology, The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK

Keywords: HIV, immunology, HAART

The first 150 words of the full text of this article appear below.

As highly active antiretroviral therapy (HAART) is available for less than one million individuals worldwide, Kaposi’s sarcoma (KS) remains a common complication of infection with the human immunodeficiency virus (HIV). Use of HAART has reduced the incidence of KS and, in affected individuals, HAART alone can lead to KS resolution. Possible mechanisms include general improvements in immune function including the specific generation of anti-KS responses, the inhibition of HIV-1 cofactors that are thought to be important in tumour development and inhibitory effects on angiogenic growth factors and cytokines that promote KS formation. The relative contributions of these mechanisms will be discussed.

Infection with HIV-1 is associated with a significant and increased risk of developing KS, a tumour that remains a significant cause of morbidity and mortality.1–3 Its aetiologic agent is Kaposi’s sarcoma-associated herpesvirus (KSHV),4 a {gamma}-herpesvirus that is widely prevalent in immunosuppressed populations, associated with all the clinico-epidemiological forms of . . . [Full Text of this Article]


   Immune reconstitution
 

   Decreases in HIV-1 on HAART
 

   Anti-angiogenic and anti-cytokine effects
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
R. Duprez, V. Lacoste, J. Briere, P. Couppie, C. Frances, D. Sainte-Marie, E. Kassa-Kelembho, M.-J. Lando, J.-L. Essame Oyono, B. Nkegoum, et al.
Evidence for a Multiclonal Origin of Multicentric Advanced Lesions of Kaposi Sarcoma
J Natl Cancer Inst, July 18, 2007; 99(14): 1086 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
M. Bower, B. Gazzard, S. Mandalia, T. Newsom-Davis, C. Thirlwell, T. Dhillon, A. M. Young, T. Powles, A. Gaya, M. Nelson, et al.
A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy
Ann Intern Med, August 16, 2005; 143(4): 265 - 273.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Bower, M. Nelson, A.M. Young, C. Thirlwell, T. Newsom-Davis, S. Mandalia, T. Dhillon, P. Holmes, B.G. Gazzard, and J. Stebbing
Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma
J. Clin. Oncol., August 1, 2005; 23(22): 5224 - 5228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Stebbing, B. Gazzard, S. Mandalia, A. Teague, A. Waterston, V. Marvin, M. Nelson, and M. Bower
Antiretroviral Treatment Regimens and Immune Parameters in the Prevention of Systemic AIDS-Related Non-Hodgkin's Lymphoma
J. Clin. Oncol., June 1, 2004; 22(11): 2177 - 2183.
[Abstract] [Full Text] [PDF]